Credit Suisse Ag I Mab Transaction History

Credit Suisse Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$3.22 - $4.86 $60,922 - $91,951	-18,920 Reduced 87.73%	2,645 $11,000
Q3 2022 Nov 10, 2022	SELL	$4.01 - $12.34 $8,176 - $25,161	-2,039 Reduced 8.64%	21,565 $86,000
Q2 2022 Aug 12, 2022	SELL	$8.27 - $18.43 $464,550 - $1.04 Million	-56,173 Reduced 70.41%	23,604 $267,000
Q1 2022 May 16, 2022	BUY	$12.54 - $46.93 $65,182 - $243,942	5,198 Added 6.97%	79,777 $1.3 Million
Q4 2021 Feb 14, 2022	BUY	$45.28 - $74.5 $882,099 - $1.45 Million	19,481 Added 35.36%	74,579 $3.54 Million

Q3 2021 Nov 12, 2021	BUY	$57.18 - $84.43 $696,852 - $1.03 Million	12,187 Added 28.4%	55,098 $4 Million
Q2 2021 Aug 16, 2021	BUY	$47.86 - $83.95 $2.05 Million - $3.6 Million	42,911 New	42,911 $3.6 Million
Q4 2020 Feb 12, 2021	SELL	$32.94 - $47.15 $739,766 - $1.06 Million	-22,458 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$27.46 - $47.03 $616,696 - $1.06 Million	22,458 New	22,458 $1.06 Million

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $130M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.